• Overview
  
• About the CABERNET study
  
• Requirements for participation
  
• Enrollment & referral
  

Clinical Studies

CABERNET

This is the Phase III study for NeoVista epiretinal beta radiation therapy. The CABERNET study is comparing the results of beta radiation therapy given in combination with two doses of the anti–vascular endothelial growth factor (VEGF) drug Lucentis to the results of treatment with multiple doses of Lucentis alone.

Learn more about CABERNET.

Visit the CABERNET study website.